NORCROSS, GA--(Marketwired - June 25, 2014) - RayBiotech, Inc. ("RBI") announced today that it has executed a master services agreement (MSA) with AmbioPharm, Inc. ("AmbioPharm"), a South Carolina-based cGMP peptide manufacturing services company. Under the terms of the agreement, AmbioPharm will receive Good Laboratory Practices (GLP)-compliant biomarker characterization services from RayBiotech under preferred pricing schedules. The financial terms were not disclosed.
Commenting on the agreement, RayBiotech's President, Chief Operating Officer and Co-founder, Ms. Rani Huang, stated, "AmbioPharm is one of the world's leading cGMP-grade peptide manufacturers. We are pleased that they have chosen RayBiotech as their provider of comprehensive, GLP-compliant, biomarker characterization services."
Dr. Chris J. Bai, the President and Chief Executive Officer of AmbioPharm, stated, "Our peptide development and manufacturing services depend upon reliable biomarker level testing at multiple levels. RayBiotech's antibody array and ELISA GLP-compliant testing services addresses a unique and critical need for AmbioPharm in our development and manufacturing process."
About RayBiotech, Inc.
In 2001, RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets. RayBiotech products are manufactured under GMP compliance and ISO 13485:2003 certification and are featured in thousands of publications, including: Nature, Nature Medicine, Science, Cell, Lancet, PNAS and many others. Offering the largest selection of protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metro Atlanta (Norcross, GA).
About AmbioPharm, Inc.
AmbioPharm, Inc. (APi) is a full-service peptide development and manufacturing company headquartered at our cGMP peptide manufacturing facility in North Augusta, SC. In our cGMP manufacturing facility in Shanghai, China, we manufacture peptides at very large scales, provide pilot manufacturing and process development, and manufacture raw materials, building blocks, and custom peptides. Our two cGMP facilities are capable of handling any manufacturing scale to produce bulk peptides to custom specifications using a wide range of skill sets in solid and solution-phase chemistry. In addition to manufacturing peptides, we also perform organic conjugations of peptides to proteins, toxoids, antifungals, KLH, and PEG.